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1. Introduction  
In the past four decades, the share of GDP being spent on health has steadily increased across 
OECD countries, from 3.8 percent in 1960 to 6.6 percent in 1980 and further to 9.1 percent in 
2006.
1 With increasing shares of GDP being spent on health, health sector performance and 
efficiency have become important issues in the health policy arena (OECD 2002; 2004). In 
particular, given the large and rising health care costs, even a small improvement in health 
system efficiency can mean large savings. Moreover, policymakers are concerned with the 
consequences of rising health expenditures on government budgets, especially in the context 
of ageing populations (Roserveare et al. 1996). How to respond to the population ageing and 
associated ramifications on health care and pension outlays is still an open question 
(Elmendorf and Sheiner 2000). It is clear, however, that to meet the rising need for health 
care services without placing strain on the public purse, improved health system efficiency is 
critical. 
There are three levels of efficiency analysis for health care services, namely the 
disease level, the sub-sector level, and the system level (Häkkinen and Joumard 2007). The 
system level takes the broadest perspective in that it examines the efficiency of a country’s 
entire health system; the disease level takes the narrowest focus to analyze the efficiency in 
dealing with individual diseases; and the sub-sector level takes the middle ground by looking 
at individual components of the health sector, in particular hospitals, nursing homes, primary 
care facilities, or physicians.
2  The system approach has an advantage that it attempts to 
encompass all components of the health sub-sectors, and thereby includes linkages between 
sub-sectors (e.g. physicians and specialists) in providing health care services. Health system 
efficiency analysis, however, is much less common than sub-sector and disease level analyses. 
The methodological problems of efficiency analysis are a major reason for this; for efficiency 
                                                 
1 The figures are based on OECD Health 2008 database. Figures for earlier years cover fewer countries. 
2 For a review of efficiency analysis in health care, see Hollingsworth (2003). 3 
 
analysis to play a larger role in actual policy deliberation, much more work is needed 
(Hollingworth and Street 2006).  The publication of the World Health Report 2000 and 
related studies (WHO 2000; Evans, Tandon, Murray and Lauer 2000, 2001) highlighted the 
importance of the topic, albeit the controversy surrounding it (see, for example McKee 2001 
and Williams 2001). Following the WHO publication, there were a series of attempts to 
address various methodological problems in measuring health system efficiency, including 
Hollingworth and Wildmand (2003) and Greene (2004, 2005). This paper, however, aims to 
address a different issue in health system efficiency analysis that has not received much 
attention in the literature, namely the appropriateness of using life expectancy at birth (LE) as 
a health system output measure and measuring inputs in per capita terms (e.g. health 
expenditure per capita). Given that estimation methods can deliver useful results only if 
outputs and inputs are measured accurately, the measurement issue raised in this paper is 
arguably of primary importance.  
Life expectancy at birth (LE) is by far the most commonly used measure of health 
system output. Although LE has been widely accepted as an average health status indicator, it 
can be a poor indicator of health system output and performance for the following reasons. 
First, even in a primitive society with no health system in place, LE would not be equal to 
zero. Therefore, using LE as an output indicator grossly overstates the value-added of the 
health system to lifespan. Furthermore, LE measurement assumes a stationary population 
whereby the population in any age-sex group is computed based on the current (or more 
precisely recent past) mortality rates of younger age groups. Therefore, LE does not capture 
the actual demographic structure of the country. By the same logic it is also inappropriate to 
compare health inputs in per capita terms unless the actual population structure is the same 
over time and across countries. For instance, a country with an aged population can have the 
same LE as a country with a young population; however, the health system that serves an 4 
 
aged population is likely to be spending more compared with a health system providing for a 
younger population. Measuring health input in per capita terms, therefore, wrongly indicates 
that the former is less cost efficient than the latter in achieving the same LE. 
Once we start to consider demographic factors, it is obvious that the contributions of 
the health system to different age-sex groups are vastly different. For instance, the reduction 
in infectious disease since 1840 reduced mortality rates of infants and children more than 
those of adults
3 (Cutler, Deaton, and Lleras-Muney 2006). Not only does the contribution of 
the health system to reducing mortality rates vary across age and sex, but also the “average 
cost” of producing a certain health output per person (e.g. additional life year saved) may 
vary for each age-sex group.  
Considering these limitations of LE, we propose a new measure of health system 
output, namely the Incremental Life Years (ILY) and its variant Relative Incremental Life 
Years (RILY). Simply put, ILY measures the value-added of the health system in terms of 
extending the longevity of its current population. Evans, Tandon, Murray and Lauer (ETML) 
(2000) also put forward a similar framework of using the observed health status above an 
estimated minimum level as a measure of the health system output.
4 Using ILY to replace LE 
obviously does not resolve all the difficulties in measuring health system output. For one, a 
significant portion of health services in developed countries are directed toward addressing 
morbidity problems, especially improving the quality of life for the elderly, without 
necessarily affecting their life spans. The methodology adopted here can be readily extended 
to include both mortality and morbidity in order to produce an output measure such as 
Incremental Healthy Life Years, though the lack of reliable and comparable morbidity data 
forces us to focus on mortality based measures in the current paper.  
                                                 
3 Improvement of public health was believed to be a contributing factor. 
4 Their health status measure is disability adjusted life expectancy (DALE). They estimate the minimum level of 
DALE from a cross-section of 25 countries at around 1908 as their baseline health status, controlling for literacy 
rate. The exact method and data are not clear as details are provided in another study, Evans, Bendib, Tandon et 
al. (2000), which apparently was not available on the WHO website anymore (date of access: 7 April, 2008). 5 
 
The rest of the paper is organized as follows. Section 2 further explains the rationale 
behind the new health system output measure and its actual construction. Section 3 applies 
the new output measures to 30 OECD countries and compares the new health output measure 
with LE. Focusing on only OECD countries can go some way to mitigate problems in relation 
to data availability and quality, as well as the heterogeneity problems inherent in the WHO 
study.
5 For illustrative purpose, in Section 4 we use the newly proposed output measures and 
data envelopment analysis method to analyze the efficiency and productivity of health 
systems of the OECD countries, and contrast the results with those obtained using LE. Here it 
should be emphasized that the objective of this paper is to contribute to the methodology of 
measuring health system output and input, additional work is needed before the results of 
cross country efficiency and productivity comparisons can provide conclusive policy 
direction. Lastly, Section 5 discusses the findings and offers some concluding remarks. 
2. A Value-added Measure of Health System Output 
2.1 Number of Lives Saved 
In the national accounts, the contribution of a sector is measured by the value-added 
generated by that sector, i.e. the gross output net of intermediate inputs used. Similarly, the 
value-added of an operation or a medical intervention, ignoring the quality of life issue, may 
be measured by the number of life years the patient will have after the operation minus the 
number of years the patient would have lived without the operation. The same principle could 
be applied to measuring the output of a hospital or the entire health system. Using LE as a 
measure of health system output violates this basic principle. Life expectancy at birth 
encompasses the effects of natural health endowment, the health system, and environmental 
factors on all age groups. Here environment is used as a general term, referring to all factors 
that can affect health but are not part of natural health endowment or health resources, such 
                                                 
5 Green (2004, 2005) explain that a key problem of the method used in WHO (2000) is that it does not account 
for the heterogeneity of the large sample of 191 countries. 6 
 
as education, and law and order. The role of natural health endowment of human beings is 
clearly evident in the fact that, even in primitive societies with no health systems LE was well 
above zero. Population studies have found that LE was about 25 years in the earliest human 
societies (Acsádi and Nemeskéri 1970), about two-thirds of the LE in many Sub-Saharan 
African countries nowadays and close to one-third of the OECD average. Simply subtracting 
this natural LE from the current LE, however, is not an appropriate measure of the value 
added of the health system. This is because the contribution of the health system to the 
reduction of mortality risks varies across age and gender, and thus the demographic structure 
of a country can make a substantial difference to actual health system output and performance, 
however, LE assumes a particular demographic structure that is unlikely to hold.  
To address the aforementioned problems, we propose a new measure—Incremental 
Life Years (ILY)—as a measure of health system output. To understand the rationale behind 
ILY, we first start with a simpler concept—the number of lives saved. Suppose we divide the 
population of country i into a number of age-sex groups. The total number of lives saved by 
the health system in a given year is equal to 
  ˆ () ii x i x i x
x
LS p p n =− ∑  (1) 
where  ix p  is  the  observed survival probability of age-sex group x in country i,   ˆix p    the 
counterfactual survival probability of the group if the health system ceased to function 
throughout the year, and  ix n  the actual population size of the group. 
Obviously  ˆix p  is not observable. To circumvent the problem, we use proxy life tables 
as a baseline measure (a number of different proxy life tables are considered with details 
given in Section 2.2). The baseline survival probabilities are assumed to be country invariant, 7 
 
i.e.  ˆix p  becomes  ˆx p .
6 Because the baseline probabilities are common to all countries, the 
value of  i LS  will depend not only on the value-added of country i’s health system, but also 
on the socio-economic conditions present in the country. Consequently variation in health 
system efficiency between countries will be affected not only by the differences in their 
health care policy and institutional settings, but also by the heterogeneity in their environment. 
The efficiency effects of policy, institutional and environment elements can be controlled by 
including those elements into the efficiency model; alternatively, they can be isolated from 
the “raw” efficiency scores using regression methods to derive efficiency scores conditional 
on those elements. However, since the main purpose of the paper is to introduce the new 
health output measure, we will abstract from this issue. Focusing on the relatively 
homogenous OECD countries helps mitigate this problem to some extent. 
2.2 Incremental Life Years (ILY) 
In equation (1), it is implicitly assumed that the value of the life saved of a young person is 
the same as that for an old person.
7 Since a young person is expected to live longer than an 
old person, it is more reasonable to measure health system output in terms of the number of 
expected life years saved rather than the number of lives saved. Here we use the total number 
of life years (expected to be) saved, or simply Incremental Life Years (ILY), which is given 
by 
  ˆˆ () ii x x x i x
x
ILY p p e n =− ∑  (2) 
Here  ˆx e  is the baseline LE of the group x and is equal to the number of years a person is 
expected to live after being saved in the current year without any assistance from the health 
                                                 
6 In ETML (2000), the baseline health status is country specific because it is conditional on the country’s 
literacy rate. Since our sample covers only the OECD countries, not controlling for the most basic level of 
education should not be a cause for concern.  
7 Because an young person saved is assumed to live longer than an old person saved, using lives saved implies a 
weighting system where a year lived by an older person is of greater value than that lived by a younger person. 8 
 
system in the future. The baseline LE instead of country i’s life expectancy (i.e.  ix e ) is used 
for the following reason. Life expectancy is calculated using mortality rates of all age groups. 
Therefore, if we were to use age-specific LE of the country itself to calculate ILY for those 
who aged, 10-14, then we would implicitly also be counting the benefit of future health 
system resources that this age group may need to receive in order to face the same mortality 
risks that their older cohorts currently enjoy. As a result, the ILY of this age group would 
have taken into account the resources received by those aged 10-14, as well as future health 
resources needed when this cohort was aged 15-19, 20-24,…etc. Obviously this is not 
desirable because we only want to consider the direct benefit of the current health provision 
and not the benefit of future healthcare provision. Using the baseline LE can mitigate this 
problem because it is assumed to reflect the additional life years gained due to current health 
care that could be expected if no health resources were provided in subsequent years. 
Consequently, there will be no double-counting of the contribution of the health system to the 
older cohorts. 
The value of ˆx e   is calculated using the information of  ˆx p   across the entire age 
spectrum using standard life table methods. In essence, we weight the number of lives saved 
for each age-sex group by the baseline LE at the age of intervention. This involves value 
judgments about the relative values of life for different age-sex groups. The current 
specification of ILY means that lives of younger people are valued more than those of elderly, 
as they will live for longer, but each of the years lived is valued the same. Whether these 
judgments are appropriate is an important question of its own. For instance, in a recent study, 
Kniesner, Viscusi and Ziliak (2004) show that because people prefer to delay consumption 
till old age, the value placed on life for the elderly actually is higher than that for the young. 
Although we are not suggesting that the simple explicit judgment currently made in ILY is 
the most appropriate one, it is nevertheless transparent, allowing open discussion and even 9 
 
modifications. In comparison, value judgments are also implicitly made when using LE as the 
output measure. Additionally, it should be emphasized that the alternative weightings will not 
change the nature of ILY as a value-added based output measure. More importantly, the 
proposed weighting can be further justified by the fact that the resulting ILY measure can be 
interpreted objectively as the expected number of life years saved if there is a one-off 
increase in health system expenditure that increases the survival probabilities for just one 
year.
8 
2.3 Average and Relative Incremental Life Years (AILY and RILY) 
If we want to compare health system performance across countries, we need to control for the 
size of the population or the number of life years that could potentially be saved by the health 
system. Otherwise we will risk overly crediting those countries that have a relatively large 
population and therefore could easily save a lot of life years at the “lower end” of the cost 
spectrum even though they may have a large amount of unmet demand at the “higher end”.
9 
To make this point clearer, consider Mexico and Austria which have a ten-fold difference in 
population size. Since the cost of saving a life is not constant but contingent on the 
circumstance, there will be a distribution (i.e. a spectrum) of intervention costs from very low 
to very high. To save, for example, 1000 lives out of its population of 8.4 million, Austria 
probably needs to work on cases of low intervention costs (e.g. diseases that can be prevented 
with low cost immunization) as well as of high intervention costs (e.g. diseases that requires 
complicated operations). On the contrary, to save 1000 lives out of its population of 108 
million, Mexico could just focus on cases of low intervention costs and ignore the high cost 
ones. If the average cost-effectiveness of intervention is independent of age and sex, this 
problem could be easily addressed by normalizing ILY by the population size, however, this 
                                                 
8 In reality, increases in survival probabilities in a given year are also likely to some extent be due to health 
investment in previous years. 
9 “Lower end” and “higher end” refer to the relative costs necessary to save a life. 10 
 
is unlikely the case and therefore ILY needs to be normalized by an index which takes into 
consideration both the population size and the relative difficulty/ease of saving life years in 
each age-sex group. 
To address this issue, we gauge the health performance of a country against some 
benchmark that automatically adjusts to the demographic structure of the country in concern. 
To that end, we propose to use the Average Incremental Life Years (AILY): 
  ˆˆ () ix x x i x
x
AILY p p e n =− ∑  (3) 
The newly constructed measure, AILY, is calculated in the same way as ILY except 
replacing  ix p  with  x p , which is the median survival probability observed amongst all the 
countries in the dataset (i.e. OECD in our case) in a given, base year.
10 AILY  therefore 
represents the total number of life years that would have been saved in a country that had the 
same demographic profile as country i but with standardized, average mortality rates  x p  in 
the based year. Note that ( ) ˆˆ x xx p pe − is the weight applied to each age-sex group and 
represents the difficulty (on average experienced by countries) for saving life years per 
population in each age-sex group, with a high value indicating that countries on average save 
a large number of life years per person in that age-sex group compared to other age-sex 
groups. In a way, ( ) ˆˆ x xx p pe −  can also be considered as a proxy for the demand for life years 
to be saved per person in each age-sex group, where the demand is assumed to be 
proportional to the number of life years saved per person in the “average” country in the base 
year.  
Normalizing ILY by AILY yields another output measure called the Relative 
Incremental Life Years (RILY): 
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Since RILY controls for the demographic structure and because it is an index measure 
defined relative to average levels, it is useful for comparing health system output across 
countries. Furthermore, as AILY can be interpreted as an index for total demand upon the 
health system,
11 using RILY to measure health system output has another important merit 
over LE in that it provides an index as to what extent the country has successfully met the 
demand for health services. 
Since RILY is equal to the actual number of life years saved relative to some 
benchmark value, it may also be considered as a type of efficiency measure reflecting the 
extent to which a health system is able to meet the demand. However, it does not take into 
account the inputs used by the country to achieve this outcome. It should also be pointed out 
that although ˆx ix en   enters both AILY and ILY, it does not cancel out the effect of 
demography on RILY, it merely moderates it. Additionally, if a country has higher than 
average survival probabilities in all the age groups, its RILY will be greater than one. 
3 Computations of ILY and RILY 
3.1 Baseline Survival Probability 
To implement the new measures ILY and RILY, we need to specify the baseline survival 
probability  ˆx p . We have experimented with the survival probabilities of four different 
populations, respectively denoted as the ancient population, US Black population in 1901, 
low income and low-middle income populations as a proxy for the baseline survival 
                                                 
11 This implies that some countries will fall short of meeting the “average” demand while others will exceed it. 
However, whether a country falls short or exceed average demand will depend on the amount of health 
resources allocated and how efficiently these are used. 12 
 
probability. In general, the survival probabilities progressively increase from the ancient 
population to the low-middle income population. 
  The survival probability of the ancient population is a measure of the natural survival 
probability of human species. It has been well established in population studies that for a 
population to be sustainable, LE must have been above 20, and for it to exceed 30, some kind 
of modern medical knowledge is required (Hopkins 1966). A LE of 25—the estimated figure 
for hunter-gatherers—is widely considered the upper limit a population can achieve without 
modern medicine (Acsádi and Nemeskéri 1970). Coale et al. (1983) has published a series of 
life tables pertaining to different development stages of human societies. At the “level 3” 
development classified by their study,
12 the LE for males and females are equal to 22.9 and 
25.0 years, respectively. We select these life tables to provide us with the data for the natural 
survival probability of human species. 
The second baseline population is the US Black population in 1901. This is the 
earliest obtainable life table for the Black population that is compatible with other life tables 
used in this study. Though slavery in the US was abolished in 1865, it is reasonable to 
assume that the Black population still received little health care services in the late 1800s, 
making their survival probability a good proxy for the natural survival probability. The LE 
for US Black males and females in 1901 are 32.5 and 35.0 years, respectively. These figures 
are comparable to the LE of present bottom African countries that are severely affected by 
the HIV/AIDS epidemic. 
The third baseline population is based on low income countries in year 2000 as 
classified by the World Bank, excluding those involved in military conflicts, or with a 
                                                 
12 Besides the level of development, the authors also distinguish four different regions in the construction of 
human life tables. The four regions are “North”, “East”, “West” and “South”. The data of natural survival 
probability is drawn from the “West” model life tables. The “West” model life tables are preferred to the other 
three because “they were based on mortality experience recorded in populations known to have relatively good 
vital statistics, and not showing a persistent systematic pattern of deviations from the preliminary model tables.” 
(Coale et al., 1983, p.12) 13 
 
HIV/AIDS prevalence over 1 percent or where no data were available. The list of the 20 low 
income countries that form this baseline population is provided in the Appendix. Year 2000 is 
chosen because this is the earlier one of the two years, 2000 and 2004, under analysis. For 
each age-sex group, the median survival probability from the 19 countries is taken as the 
baseline survival probability for the low income group. The LE of males and females for this 
baseline population are respectively 58.5 and 61.1 years. 
The fourth baseline population is based on the low income countries plus the lower-
middle income countries in 2000 as classified by the World Bank. Again, after excluding 
countries in military conflicts, or with a high HIV/AIDS prevalence, or those where no data 
were available, the median survival probabilities from the remaining 63 countries are used as 
the baseline measures. The male and female LE’s for this baseline population are respectively 
64.0 and 69.0 years. This group is labeled “low-middle income” group. 
Each of the four selected baseline populations has its limitations. Using the ancient 
population is likely to overstate the valued added of modern day health systems by attributing 
to it the effects of improvement in nutrition, basic education and eradication of certain types 
of diseases in the past few decades (Culter et al. 2006). Even if we define the health system 
very broadly, the ILY based on the ancient population will still measure the cumulative 
valued added of the health system over decades rather than over a single year. The US Black 
population has a similar limitation, but to a lesser extent. However, it is based on a single 
country data. The low income populations are less country specific than the US Black 
population and takes into account at least to some degree the eradication of diseases and 
improvements in basic education, but African and Middle Eastern countries are overly 
represented in this group. By including more countries from other continents, the low-middle 
income population increases the degree of generalization compared with using just the low 
income countries. Nevertheless, since a functioning health system may be in place in many 14 
 
low-middle income countries, their survival probabilities may not truly indicate the 
counterfactual survival probabilities in the absence of health systems.
13 On balance, the low 
income population is our preferred baseline population. Despite this, we still report the results 
based on other baseline populations in order to demonstrate the robustness of the RILY 
measure to the choice of the baseline population. 
3.2 Estimates of Health System Output for OECD Countries 
We estimate health system output using the new measures proposed in the study, ILY and its 
variant RILY, for 30 OECD countries for the years 2000 and 2004. Two years are chosen in 
order to examine efficiency changes in these countries over time. To make the output 
measures of the two years commensurable, we need to apply the same median survival 
probability observed amongst all the countries,  x p , in calculating AILY for both years. Either 
the median values of year 2000 only, or year 2004 only, or both years can be used, but, given 
the two years are not that far apart and the rate of decline in mortality figures is quite stable 
across age-sex groups, the choice will make little difference. In this paper, we use the median 
values of year 2000, but, will also provide the result using the median values of year 2004 as 
a robustness test. Data for the OECD countries are drawn from the OECD Health Data 
2008.
14 Mortality data for the US Black population are drawn from the Human Life-Table 
Database.
15  Mortality data for low and low-middle income countries are drawn from the 
WHO Statistical Information System (WHOSIS).
16  
The estimates of ILY and RILY are shown in Table 1, alongside with LE. The 
variation in LE amongst the OECD countries, while it exists, is limited. For instance, in year 
2000, the coefficient of variation (i.e. standard derivation divided by the mean) is merely 
equal to 0.03, with the highest LE (Japan) being equal to 1.18 times that of the lowest one 
                                                 
13 We have made an adjustment for this in terms of health expenditure, see section 4.2. 
14 http://www.oecd.org/health/healthdata 
15 http://www.lifetable.de/ 
16 http://www.who.int/whosis/en/ 15 
 
(Turkey). As explained before, since LE is a measure of health status rather than the value-
added of the health system, these figures clearly understate the gap between health system 
outputs amongst countries. When RILY(ancient) and RILY(US Black) are used as health 
system output measures, the result remains largely the same. However, when RILY(low 
income), and RILY(low-middle income) are used instead, the picture changes dramatically. 
The coefficient of variation has increased to 0.12 and 0.23 respectively. Although Japan and 
Turkey are also of the highest and lowest RILY values, respectively, the ratios now increase 
to 1.80 (RILY(low income)) and 4.12 (RILY(low-middle income)). The ratio of 1.80 seems 
more plausible than the alternatives, supporting our choice of the low income population as 
the preferred baseline. 
  Despite the differences between LE and the four RILY measures, they are in general 
highly correlated, as illustrated in Figure 1. Notwithstanding the high correlation, one should 
be cautious not to jump to the conclusion that the new output measures are merely a rescaling 
of the LE and therefore will have no further implication. As will be seen next, the new output 
measure (together with the corresponding new input measure) leads to very different 
outcomes in terms of efficiency and productivity assessment. 
4. Measuring Efficiency and Productivity of Health Systems 
In this section, we demonstrate how ILY and RILY constructed in the previous section can be 
used to analyze the efficiency and productivity of OECD health systems. The discussion 
starts with an analytical framework, followed by the modeling method and specification, and 
then the empirical results. 
4.1 Analytical Framework 
Efficiency, in standard production economics, refers to the output produced, relative to what 
could have potentially been produced with a given set of inputs and production technology. 16 
 
Thus, measuring health system efficiency implies a production function that transforms 
health inputs into health output. Suppose a health system production function can be 
represented with the following general form: 
(, , , ) it it it t it HealthSystemOutput f demography healthresources technology efficiency =  (5) 
Demography is a key factor in driving the demand for health services in that ill people 
are a necessary “input” in order to save life years. In the current setting, technology is 
considered global and shared by all OECD countries but may change over time. In the case 
where LE is used as a measure of health output per capita, the output of the whole health 
system will be equal to LE multiplied by the population, or total life expectancy (TLE). For 
the purpose of exposition, we assume a Cobb-Douglas function form for (.) f
17: 
  () ( ) it t it it it TLE A HR POP
α β θ =  (6) 
where  t A  represents the technology available to all health systems at time t; and  it HR ,  it POP  
and  it θ   respectively represent the level of health resources, the population size, and the 
efficiency of country i at time period t (0 1 it θ ≤ ≤ ). 
Equation (6) implies that for a given demographic structure, technology and 
efficiency level, there are diminishing returns to health spending. This is because, to 
maximize the effects of health spending, typically the life years that are the cheapest to save 
will be saved first; as a result, the cost of saving an extra life year will increase as each 
additional life year is saved. The equation also implies for a given technology, efficiency and 
health resources, TLE increases with diminishing returns to POP. Suppose the population 
increases by duplicating the original population (twice as many “sick people”) but the total 
health resources is held constant. If the authority shifts some of the resources previously used 
to treat the relatively more expensive cases of the incumbent residents (all the cheap cases of 
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the incumbents are still dealt with) to the cheaper cases of the new arrivals, then the 
additional cheap cases that can be treated will be more than the expensive cases (that are now 
neglected), and therefore the total number of life years saved will increase. However, since 
some of the expensive cases are no longer being treated, the total increase in TLE will be less 
than double; hence population has diminishing returns to life years saved.
18 
If the production function is of constant returns to scale (CRS), i.e.  1 α β += , then (6) 
can be easily made to resemble the per capita form commonly seen in the literature: 
  /( / ) it it it t it it it LE TLE POP A HR POP
α θ ==  (7) 
In other words, the use of (7) in the literature actually implicitly assumes the health 
production technology is of CRS with respect to health resources and population size. This 
assumption, however, has rarely been tested. Thus, our empirical analysis will be based on 
(6) instead, though the applicability of (7) will be tested. 
When ILY instead of TLE is used to measure health system output, the production 
function becomes: 
  () ( ) it t it it it ILY B HR AILY
γ φ φ =  (8) 
where  t B  is a counterpart of  t A  and  it φ  is a counterpart of  it θ . 
it AILY  is used instead of the total population because it takes into account the fact 
that the proportion of “ill” people and therefore demand for health resources is likely to be 
different for each age-sex group. Here  it AILY  represents the number of life years that would 
have been saved for the population in country i at time t if the country was like an “average” 
country in terms of health resources, health system performance and the available technology 
at some base year (2000 in our case). Therefore,  it AILY  is a function of demography for 
                                                 
18 To double the total TLE it is required to provide treatment to both the cheap and expensive cases of the 
incumbents and new arrivals to the extent the incumbents originally received. 18 
 
country i in the current time period t, the global technology in the base year, and average 
health resources and average efficiency for countries in the base year. It should therefore be 
noted that the only reason  it AILY  changes is due to differences in the demographic structure 
of the population both over time and across countries and, as such, any technology growth is 
captured within  t B  and any efficiency differences both across countries and over time are 
captured within  it φ . This implicitly assumes that the technology growth and efficiency growth 
is the same for all age-sex groups which may be an appropriate approximation in the short-
run but may be less appropriate in the long-run.  We will show later that the choice of the 
base year average technology, health resources and efficiency within  it AILY  over our 4 year 
window has little effect on our results. 
The reason why  it AILY  is used as an input can be understood in the case of a CRS 
production function, in which (8) can be simplified into 
  /( / ) it it it t it it it RILY ILY AILY B HR AILY
γ φ ==  (9) 
This equation indicates that the number of life years that are saved relative to what would 
have been expected to be saved in the “average” country if it had the identical demography to 
country i in time period t . This will be a positive function of health resources used per 
expected life year to be saved in the average country for the given demography, or, in other 
words, health resources used per unit of demand. 
As explained before, RILY is a weighted per capita measure, and as such is similar to 
LE. Again, since we cannot presume CRS, we use (8) for our empirical work and compare 
the results with (6). 
4.2 Data Envelopment Analysis and Model Specification 19 
 
In total we estimate five main models (plus additional models for sensitivity tests). The 
specifications for each model are listed in Table 2. Since the purpose of this paper is to 
illustrate how the new output measure can affect performance assessment, we use the 
simplest model specification possible. The results using alternative model specifications will 
be discussed later. Besides health expenditure, the other input is either the total population or 
AILY, depending on the output measure used. There are five different output measures, 
namely TLE (corresponding to the total population input measure) and the four alternative 
measures of ILY which are constructed using different proxies for baseline mortality 
(corresponding to different AILY input measures). 
Health outputs are measured for years 2000 and 2004. The corresponding health 
expenditures of the same years are measured in purchasing power parity, constant 2000 
international dollars. The measure includes both public and private expenses, and is defined 
as the sum of expenditure on activities in relation to health promotion, prevention, curing, 
caring, and administration.
19 We use real expenditure per capita which has been adjusted for 
price level differences across countries and for movements over time. Different health input 
figures are used according to which health output measure is used. When TLE is used as the 
health output measure, health input is measured simply in total health expenditure, and the 
size of the population is used as a proxy for the demand of health services. When ILY is used 
as the output measure, the health expenditure needs to be modified in some cases. In the case 
of the ancient and US Black populations, it is reasonable to assume their health expenditure 
would have been negligible. The same assumption cannot be made for the low and low-
middle income populations though. To correct for this, we deduct the median per capita 
health expenditure of low (and low-middle) income countries from the per capita health 
                                                 
19 For detail definition, see OECD Health Data 2008 dataset. 20 
 
expenditure of each of the OECD countries, and then multiply the resulting value with the 
population of the country to obtain net total health expenditure. 
Estimates of efficiency of health systems depend on the underlying production 
frontier of the systems. The production frontiers can be identified using both the non-
parametric, data envelopment analysis (DEA) method, and the parametric, stochastic frontier 
analysis (SFA) method. The SFA method has the advantage of controlling for random noise 
in data. However, the SFA estimation results show that the random noise component is very 
small compared to the inefficiency component
20. Therefore, we adopt the DEA method 
because it does not require prior specification of the functional form of the production 
technology. The DEAP program (Coelli et al., 2005) is used for the computations. 
Before considering the results we quickly review the basic terminology used in the 
standard efficiency and productivity measurement literature (see Coelli et al. 2005 for a more 
detailed discussion). There are a number of different measures of efficiency and this paper 
focuses on those most commonly used concepts in the health literature, namely the output 
orientated technical efficiency, which represents the proportion by which outputs of a country 
can feasibly be expanded given the technology and the level of inputs. When we examine 
health system efficiency over time, we can measure a number of aspects associated with 
health system performance. First, we can measure technical efficiency change (EFFCH) 
which provides an indication of the performance of the system vis-à-vis the technology in 
different periods. Technical efficiency change (EFFCH) can be decomposed into pure 
technical efficiency change (PECH) and scale efficiency change (SECH): 
ii i EFFCH PECH SECH =×  where the scale efficiency change due to changes in the scale of 
production. If the production technology exhibits constant returns to scale (CRS), SECH will 
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noise, is over 0.95 in all estimations, and mostly over 0.97. The SFA estimation is based on the assumption of a 
Cobb-Douglas production function with time dummies. 21 
 
be equal to one, i.e. there is no efficiency gain or loss by alternating the scale of production. 
In addition, it is also possible to measure technical change (TC) when there is a shift in the 
production frontier. Technical change measures the degree by which output can be increased 
by an efficient firm using the same inputs but with the new technology available in the new 
period. The components EFFCH and TC are combined to obtain the Malmquist productivity 
index (MPI) that measures the change in total factor productivity (TFP) over a given period 
of time.  
4.3 Efficiency Scores 
The top panel of Table 2 presents various models with different combinations of inputs and 
outputs used in the study. The bottom panel of Table 2 shows the average efficiency scores, 
averaged over all the countries for a given year
21. The country specific efficiency scores, 
under different models, are presented in Table 3. It can be seen that the efficiency scores from 
different models can vary substantially, especially for Hungary and Turkey. Using total life 
expectancy (TLE) as an output measure tends to generate the highest efficiency scores and 
ILY(low-middle income) the lowest efficiency scores. This result is due to the fact that TLE 
measures the gross health status of countries rather than value-added of their health system 
and, thus, tend to compress the differences in performance between countries. Amongst the 
four ILY measures, ILY(low-middle income) is based on the highest baseline mortality rates 
and thus tends to magnify the performance differences between the countries.  
Based on our preferred baseline population—low income population, the health 
systems of Japan, Korea and Mexico are the most efficient (with an efficiency score of 1.00) 
in both years and are considered as “peer” countries that define the best performance for 
other countries. The finding of Mexico as being one of the most efficient OECD countries in 
providing health care services may raise questions for some. Here it is important to remember 
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that, due to Mexico’s input mix (i.e. a low level of health expenditure), it is only being 
compared with similar countries, such as Czech Republic, Hungary, Poland, Portugal, 
Slovakia and Spain; thus it can only be concluded that it is the best performing country within 
this group. We also need to be aware that this is a limitation of having a small sample and 
thus care must be taken when interpreting the results (in particular for TC and the TFP). The 
health system of Hungary is ranked the most inefficient in almost all models for both years, 
followed by the US.
22 
In order to examine differences between models it is more useful to analyze the 
relative performance of the countries. To this end, the correlations of the efficiency scores 
across the models are shown in Table 4. From Panels I and II, it can be seen that the 
correlations between the efficiency scores of the model that uses LE as health output measure 
and those that use ILY vary from 0.97 to as low as 0.54. Figure 2 shows a scatter plot of the 
efficiency scores from the ILY-based models against those from the TLE-based model.  
Besides the levels of technical efficiency in year 2000 and 2004, we have also 
estimated technical efficiency change (EFFCH) across the two years. Again, Table 2 shows 
the average results across countries. Detailed country-specific results are presented in Table 5 
where estimates of EFFCH, TC and TFP change are presented for different output measures.  
Efficiency change figures less than unity indicate a drop in efficiency when the country is 
assessed against the frontier production function in each time period. An EFFCH of 0.999 in 
the TLE model means that efficiency falls by 0.1 percent over the two periods. Figures in 
Table 2 show that on average there is little scale efficiency change (SECH). In fact, not only 
is the average SECH close to one, but also the SECH for each individual country, implying a 
CRS production technology for OECD countries.
23. Assuming CRS means that we can focus 
on technical efficiency change rather than pure technical efficiency change. It can be seen 
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Turkey and the US the third. Also, for the year 2000 ILY(low income) model, the US comes third after Turkey. 
23 Estimation results from SFA also indicate that the health production function is of constant returns to scale. 23 
 
that on average, changes in technical efficiency are not that large; however, the details results 
reported in Table 5 show that there are substantial variations of EFFCH across countries. In 
particular, a few countries register large improvement in efficiency for the ILY(low income) 
model, including Turkey, Italy, Portugal, Poland and Hungary. On the other hand, Slovakia, 
Spain, New Zealand and Czech Republic show the biggest declines in their efficiency scores 
from 2000 to 2004. 
  In the bottom panel of Table 2, we also report summary measures of technical change 
and TFP change over the periods 2000 to 2004 averaged across the countries. Both of these 
measures show, on average, a decline over the period when either the ancient or the US Black 
are used as the baseline population. However, when low and low-middle income populations 
are used, on average, a TFP growth of 0.2 and 1.5 percent are reported respectively. In 
contrast the technical change is of an order of 0.3 and 0.4 percent when low income and low-
middle income populations are used as the reference group.  
  In assessing TC and TFP growth it is also important to examine country-specific 
growth rates. In Table 5, we find significant variation in the performance across countries. In 
general, most of the developed or high-income countries seem to perform quite well 
irrespective of which reference population is actually used. An interesting point to note here 
is that the performance of these countries is significantly higher when low and low-middle 
income countries are used as the baseline population. For example, the United States shows a 
technical change of 3.9 percent and 5.5 percent in the ILY(low income) and ILY(low-middle 
income) models respectively compared to 1.3 and 1.1 percent in the TLE and ILY(ancient) 
models. 
  Examining the correlation between results for efficiency change based on TLE against 
the alternative efficiency change measures based on ILY, we find that these correlations are 
quite low ranging from 0.29 to 0.48 (see Panel III in Table 4). In contrast the correlations for 24 
 
efficiency change within the different measures of ILY are quite strong ranging from 0.89 to 
0.99. Very diverse correlation coefficients are also observed for TFP changes (see Panel IV in 
Table 4). Figures 3 and 4 are scatter plots of EFFCH and TFP changes of models based on 
ILYs against that based on TLE. The figures illustrate the use of ILY-based output measures 
can substantially change the relative performance of health systems across OECD countries 
as compared to LE-based measure. The reason why TFP changes are also highly diverse 
amongst the ILY-based measures is that the sample size is small and that all countries 
increase health expenditure over the time period. In particular, Turkey and Mexico act as 
outliers because while they form part of the frontier in both periods, for most specifications 
considered, in the second time period they lie inside the original frontier, This can be seen in 
Figure 4 which is a diagrammatic illustration of the DEA frontier for the low income baseline 
for both years 2000 and 2004 assuming CRS. This may therefore suggest either that there has 
been technical regression in this part of the production function (which is unlikely) or that 
these countries were not fully efficient in the year 2000 and were still not fully efficient in the 
year 2004 (which is more likely)
24. For this reason caution should be exercised when 
interpreting the results of TE, TC and TFP especially for the low expenditure countries.  
4.4 Sensitivity tests 
In order to assess the robustness of our general findings, we conduct a number of sensitivity 
tests. First, AILY can be constructed using the median survival probability of low income 
countries in year 2004 instead of year 2000. We find that changing the base year for the 
construction of AILY has very little effect on every measure. Second, we have added 
education expenditure as an additional input. For instance, for our preferred output measure, 
ILY(low income), the new and original efficiency scores have a correlation of 0.74 for 2000 
and 0.92 for 2004, and the correlation of efficiency change is 0.50. This result is mainly 
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driven by the fact that one or two more countries that were previously close to the frontier are 
now on the frontier, which is not surprising because with a small sample adding additional 
inputs in the DEA can increase the number of peer countries on the frontier and this 
substantially change the findings. We also prefer not to include education expenditure in the 
models because in the SFA estimations undertaken, the education expenditure variable is 
highly correlated with health expenditure and is not always significant for all model 
specifications. 
  In SFA estimation, the model using ILY(low-middle income) does not converge
25 
with and without education expenditure. Also, while the models based on TLE, ILY(ancient) 
and ILY(US Black) do not reject the hypothesis of a CRS Cobb-Douglas production function 
at the 1 percent level, the model based on ILY(low income) does not reject the hypothesis 
only at the 5 percent level. 
  Overall, it can be concluded that the estimation results do exhibit a degree of 
sensitivity towards estimation methods and model specifications. The choice of baseline 
population also appears to have significant influence on some of the results. This type of 
sensitivity, however, is not uncommon in efficiency analysis. And it should be reiterated that, 
the objective of the paper is to improve on the methodology of measuring health system 
output and inputs, not the methodology of efficiency analysis itself. We believe that the 
results in particular for the EFFCH based on the DEA methodology are robust and provide 
interesting insights into the change in performance of health systems for the OECD countries. 
5. Discussion and Conclusion 
Measuring health system efficiency is a highly desirable yet difficult task. This paper has 
illustrated the importance of considering a country’s demographic structure when measuring 
both health output and health input. Firstly, a new, improved health system output measure, 
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namely the Incremental Life Years (ILY), and its variant Relative Incremental Life Years 
(RILY) that takes demographic structures into consideration were constructed. Second, a 
related health system input measure, namely the Average Incremental Life Years (AILY) that 
arguably is a better proxy for health services demand than total population size, was also 
constructed. These new measures were then applied to estimating health system efficiency of 
OECD countries to demonstrate the differences compared with those results obtained from 
the regularly used LE output measure and health expenditure per capita as the input measure.  
A fundamental conceptual difference between ILY and the traditional output 
measure—life expectancy at birth—is that ILY measure the value-added of the health system 
rather than the health status of population. This is achieved by subtracting baseline survival 
probabilities from those observed. Measuring against some baseline is a common practice in 
many economic indicators such as price indexes or real GDP. The empirical results reported 
in sections 2 and 3 show that correcting for the baseline survival probabilities can result in 
significant differences, not only in the measures of health output and health system efficiency, 
but also in the gauging efficiency and productivity changes.  
The difference in the efficiency scores (and their correlations) and change in 
efficiency scores across the ILY models and TLE model has demonstrated that large errors 
could result when LE (gross output) rather than ILY (value-added based measures) are used 
to measure health system output. Simply adjusting LE by subtracting a baseline value from it, 
instead of doing so for each individual age-sex group as in the case of ILY, is not advisable. 
While it may seem to be a convenient short cut, it fails to account for differences in 
demographic structures—another advantage of ILY. As some countries face rapidly aging 
populations these differences in demographic structures play an increasingly important role in 
terms of explaining differences in health system expenditure and outputs across countries; LE 
and health expenditure per capita do not capture these demographic factors. 27 
 
While the ILY and RILY measures constructed in this paper are arguably better health 
system output measures than LE, the proxy nature of baseline survival probabilities means 
that their values are likely to be subject to some errors. In comparison, using LE as a health 
output measure appears to be clean and easy to understand, but this simplicity masks the fact 
that it is equivalent to setting the baseline survival probabilities to zero, using the current 
mortality of older age groups in the countries to weight each life saved and assumes a 
particular demographic structure, all of which are unrealistic and extreme cases compared to 
the four baselines and methods used in this paper.  Simply put, the approach proposed in this 
paper, in Warren Buffett’s famous words, is that “it is better to be approximately right than 
precisely wrong.” 
It should be stressed that the development of ILY and RILY in this paper should be 
considered a step on the journey towards achieving more accurate measures of health system 
output and efficiency measurement, rather than the finishing line. Its primary function is to 
establish the importance of measuring health output as value-added, accounting for 
demographic factors in output measurement and, therefore, making the assumptions 
underlying health system output measurement explicit rather than implicit. If these elements 
are properly acknowledged, then efforts can focus on better measures of counterfactual 
survival probabilities and more appropriate assumptions and weightings, which will 
eventually lead to more accurate measures of health system output and efficiency. 
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Table 1 Life Expectancy at birth (LE), Incremental Life Years (ILY), Relative Incremental Life Years (RILY)
*  
   2000  2004 
     Level 3  US Black  Low income  Low-middle income     Level 3  US Black  Low income  Low-middle income 
Country  LE  ILY  RILY ILY  RILY  ILY RILY ILY  RILY  LE  ILY  RILY ILY RILY ILY RILY ILY RILY 
Australia  79.80 14623875  1.014  11666271 1.023  4659231 1.065 2960303  1.111 80.75  15119967  1.023  12113460  1.038 4998874 1.104 3278685 1.177 
Austria  78.50 5761841  1.006 4532145  1.010  1848280 1.027 1197111  1.045 79.30 5738031  1.015 4524173 1.024 1914342 1.064 1281535 1.105 
Belgium  77.80 7493368  0.999 5871921  0.999  2368280 0.996 1498713  0.994 78.45 7532311  1.006 5917583 1.009 2452980 1.026 1593157 1.042 
Canada  79.10 22893213  1.011  18183073 1.018  7242970 1.050 4615269  1.084 80.20  23713938  1.021  18956217  1.034 7835199 1.093 5165166 1.154 
Czech  Rep  75.05 6718914  0.970 5262605  0.951  1874648 0.868 1070474  0.782 75.90 6839720  0.978 5356533 0.963 1997350 0.904 1190825 0.844 
Denmark  76.85 4000922  0.992 3125660  0.987  1223082 0.965  745160  0.941 77.65 4005050  0.999 3142395 0.997 1258038 0.996  790014  0.993 
Finland  77.60 3733754  0.996 2943116  0.994  1160965 0.985  725343  0.976 78.70 3767114  1.007 2993043 1.012 1228710 1.029  797644  1.048 
France  79.10 46844296  1.010 37107174  1.017  15170863 1.042  9692909  1.070  79.70 48169532  1.015 38256981 1.027 15957956 1.067 10400165 1.112 
Germany  77.90 57468772  1.000 44960056  1.000  18407273 1.002 11925623  1.004  79.10 57574302  1.013 45243223 1.021 19411073 1.057 13117310 1.092 
Greece  78.05 7413655  1.002 5825608  1.001  2380000 1.009 1541366  1.016 79.20 7636187  1.014 6014830 1.021 2574561 1.061 1726048 1.100 
Hungary  71.55 6525868  0.927 4963405  0.883  1467166 0.665  617770  0.443 72.80 6581228  0.941 5033177 0.905 1627646 0.736  793042  0.564 
Iceland  79.60 223850  1.013  179315 1.021  70831 1.065 44107  1.115  80.65  229250  1.021  184245  1.033 74693 1.101 48076 1.177 
Ireland  76.40 2866409  0.989  2272891 0.982  831195 0.952 479651  0.917  77.95  3067440  1.002  2447269  1.003 938225 1.012 569018 1.022 
Italy  79.00 40949942  1.012 32162685  1.019  13731847 1.053  9187367  1.085  80.65 41941296  1.029 33131451 1.048 14857622 1.123 10345129 1.196 
Japan  81.15 91493362  1.030 73627023  1.051  32366620 1.131 22408766  1.213  82.20 92954258  1.041 74512849 1.071 34301231 1.176 24516510 1.279 
Korea  74.65 34454172  0.978  27384499 0.966  9060183 0.891 4769536  0.804 76.75  33216540  0.993  26550662  0.988 9419248 0.965 5515935 0.940 
Luxembourg  78.15 334017  1.002 263357  1.004  104729 1.011  65332  1.020  78.50 348127  1.006 274833 1.009 110579 1.027  70057  1.045 
Mexico  74.20 87052353  0.965 69182593  0.948  20315683 0.794  8236843  0.596  74.40 88878256  0.969 70711477 0.953 21369796 0.818  9252877 0.648 
Netherlands  78.05 11885789  1.003 9390490  1.004  3733009 1.015 2337220  1.026 79.20  12103917  1.013 9626474 1.020 3944452 1.059 2561158 1.099 
New  Zealand  78.25 2971287  1.003  2357796 1.005  899233 1.012 542536  1.020  79.65  3090546  1.013  2469032  1.021 976584 1.057 611698 1.098 
Norway  78.65 3468533  1.007 2726308  1.011  1109405 1.031  702814  1.053 79.65 3463892  1.016 2743096 1.027 1146536 1.075  751557  1.125 
Poland  73.85 25582975  0.961  20028103 0.938  6573167 0.815 3422986  0.686 74.90  25539029  0.970  20095399  0.952 7009113 0.862 3917345 0.769 
Portugal  76.40 7415047  0.985 5810535  0.975  2206343 0.930 1318754  0.885 77.55 7611536  0.996 5962710 0.993 2373900 0.982 1488881 0.970 
Slovakia  73.25 3589367  0.958  2803643 0.932  900732 0.799 453645  0.657  74.15  3648773  0.965  2859419  0.943 968701 0.838 518224 0.726 
Spain  78.75 28219099  1.008  22284223 1.014  9214257 1.037 6028675  1.061 80.10  29312514  1.021  23170165  1.036  10024013  1.092 6779466 1.150 
Sweden  79.70 6501167  1.019 5129715  1.030  2216403 1.084 1492231  1.136 80.55 6628865  1.027 5267579 1.044 2329014 1.118 1599967 1.192 
Switzerland  79.80 5343307  1.018 4232934  1.029  1777516 1.078 1177140  1.130 80.80 5401473  1.027 4303476 1.045 1858869 1.121 1267417 1.199 
Turkey  68.95 50598444  0.933  39370057 0.897  9699595 0.629 2527311  0.295 71.00  52181100  0.948  40918650  0.920  11247346  0.713 4115887 0.463 
United  Kingdom  77.00 43575670  0.993 33924702  0.987  13283212 0.968  8165843  0.946  78.65 43991332  1.009 34705118 1.014 14285371 1.039 9263626  1.064 
United States  76.75  214701499  0.991  169521602  0.986  63167806  0.951  36751929  0.914  77.60  224390507  0.997  177944558  0.997  67910165 0.982 40709911 0.968 
                                              
Average  77.13  28156825  0.99  22236450 0.99  8302151 0.96 4890091  0.93 78.22  28822534  1.00  22847669  1.01 8880073 1.01 5467878 1.01 
Coefficient  of  variation  0.03  1.53  0.02 1.53  0.04  1.54 0.12 1.57  0.23  0.03 1.55  0.02 1.55 0.04 1.54 0.11 1.55 0.20 
* The estimations of RILY are based on the median survival probability observed in year 2000. 31 
 
 
Table 2 Model specification and average results 
 
   Models 
   TLE  ILY(ancient)  ILY(US Black)  ILY(low income)  ILY(low-middle income)
Inputs          
Total Health Expenditure*  X  X  X  X  X 
Total population  X             
AILY (ancient)    X       
AILY (US Black)        X       
AILY (low income)        X   
AILY (lower-middle income)              X 
Output         
TLE  X             
ILY (ancient)    X      
ILY (US Black)        X       
ILY (low income)      X   
ILY (lower-middle income)              X 
Average Results          
Technical efficiency (TE) 2000  0.937  0.979  0.964  0.914  0.863 
Technical efficiency (TE) 2004  0.972  0.977  0.961  0.913  0.868 
Technical efficiency change (EFFCH)  0.999  0.998  0.997  0.999  1.011 
Technological change (TC)  0.996  0.995  0.998  1.003  1.004 
Pure technical efficiency change (PECH)  0.998  0.999  0.998  1.000  1.010 
Scale efficiency change (SECH)  1.000  1.000  0.999  0.999  1.001 
Total Factor Productivity (TFP) change  0.995  0.993  0.995  1.002  1.015 
 
 




Table 3 Technical Efficiency (TE) Scores based on Data Envelopment Analysis 
 
  Year 2000  Year 2004 
  TLE  ILY(ancient)  ILY(US Black)  ILY(low income) ILY(low-mid income)  LE  ILY(ancient)  ILY(US Black)  ILY(low income)  ILY(low-middle income)
Australia  0.983  0.985  0.974 0.941  0.916 0.982  0.982  0.969  0.939  0.920 
Austria  0.967  0.977  0.962 0.908  0.861 0.965  0.974  0.956  0.905  0.863 
Belgium  0.959  0.970  0.951 0.881  0.820 0.954  0.966  0.943  0.872  0.815 
Canada 0.975  0.981  0.969 0.928  0.894 0.976  0.980  0.966  0.929  0.902 
Czech  Rep  0.982  0.979  0.963 0.925  0.902 0.973  0.973  0.952  0.898  0.852 
Denmark  0.947  0.963  0.939 0.853  0.776 0.945  0.959  0.931  0.847  0.776 
Finland 0.970  0.979  0.965 0.916  0.866 0.965  0.974  0.959  0.898  0.840 
France  0.975  0.980  0.968 0.921  0.882 0.970  0.975  0.959  0.907  0.869 
Germany  0.960  0.971  0.952 0.886  0.828 0.962  0.973  0.954  0.899  0.853 
Greece 0.962  0.972  0.953 0.892  0.838 0.964  0.973  0.954  0.903  0.860 
Hungary  0.942  0.941  0.902 0.733  0.546 0.937  0.939  0.900  0.744  0.588 
Iceland 0.981  0.984  0.971 0.942  0.920 0.981  0.980  0.965  0.937  0.920 
Ireland  0.950  0.972  0.953 0.871  0.768 0.948  0.963  0.937  0.861  0.798 
Italy  0.974  0.982  0.970 0.930  0.895 0.981  0.988  0.979  0.955  0.935 
Japan  1.000  1.000  1.000 1.000  1.000 1.000  1.000  1.000  1.000  1.000 
Korea  0.989  0.999  0.996 1.000  1.000 1.000  0.999  0.996  1.000  1.000 
Luxembourg  0.963  0.973  0.955 0.894  0.841 0.955  0.966  0.943  0.873  0.817 
Mexico  1.000  1.000  1.000 1.000  1.000 1.000  1.000  1.000  1.000  1.000 
Netherlands  0.962  0.974  0.956 0.897  0.846 0.964  0.972  0.953  0.901  0.859 
New  Zealand  0.984  0.994  0.988 0.965  0.921 0.980  0.987  0.977  0.934  0.868 
Norway 0.969  0.977  0.962 0.912  0.869 0.969  0.976  0.959  0.914  0.880 
Poland  0.990  0.987  0.976 0.968  1.000 0.996  0.989  0.980  0.983  1.000 
Portugal  0.962  0.972  0.953 0.885  0.817 0.966  0.975  0.957  0.900  0.843 
Slovakia  0.981  0.983  0.969 0.945  0.945 0.971  0.975  0.956  0.899  0.833 
Spain  0.996  0.996  0.991 0.992  1.000 0.982  0.987  0.977  0.948  0.918 
Sweden  0.982  0.989  0.981 0.958  0.937 0.980  0.986  0.975  0.951  0.931 
Switzerland  0.983  0.988  0.979 0.953  0.932 0.983  0.986  0.976  0.954  0.937 
Turkey  1.000  0.967  0.946 0.792  0.510 1.000  1.000  0.987  0.907  0.772 
UK  0.956  0.972  0.952 0.883  0.811 0.957  0.969  0.947  0.884  0.832 




Table 4 Correlation of results across models 
 
Panel I: Technical Efficiency (TE) 2000    
 TLE  ILY(ancient)  ILY(US  Black)  ILY(low  income)  ILY(low-middle  income) 
TLE 1.00         
ILY(ancient) 0.82  1.00       
ILY(US Black)  0.82  1.00  1.00     
ILY(low  income)  0.70 0.97 0.96 1.00   
ILY(low-middle  income)  0.54 0.87 0.87 0.97  1.00 
         
Panel II: Technical Efficiency (TE) 2004    
 TLE  ILY(ancient)  ILY(US  Black)  ILY(low  income)  ILY(low-middle  income) 
TLE 1.00         
ILY(ancient) 0.97  1.00       
ILY(US Black)  0.96  0.99  1.00     
ILY(low  income)  0.91 0.93 0.96 1.00   
ILY(low-middle  income)  0.80 0.83 0.87 0.97  1.00 
          
Panel III: Technical Efficiency Change (EFFCH)       
 TLE  ILY(ancient)  ILY(US  Black)  ILY(low  income)  ILY(low-middle  income) 
TLE 1.00         
ILY(ancient) 0.43  1.00       
ILY(US Black)  0.48  0.99  1.00     
ILY(low  income)  0.47 0.97 0.96 1.00   
ILY(low-middle  income)  0.29 0.92 0.89 0.96  1.00 
          
Panel IV: Total Factor Productivity (TFP) Change      
 TLE  ILY(ancient)  ILY(US  Black)  ILY(low  income)  ILY(low-middle  income) 
TLE 1.00         
ILY(ancient) 0.95  1.00       
ILY(US Black)  0.95  0.99  1.00     
ILY(low  income)  0.76 0.75 0.81 1.00   





Table 5 Technical Efficiency Change (EFFCH), Technical Change (TC) and Total Factor Productivity Change (TFPCH) over 2000 to 2004 
 
  TLE ILY(ancient)  ILY(US  Black)  ILY(low  income)  ILY(low-middle  income) 
  EFFCH  TC  TFPCH EFFCH  TC  TFPCH EFFCH  TC  TFPCH EFFCH  TC  TFPCH  EFFCH  TC  TFPCH 
Australia  0.999  1.013  1.012 0.998  1.008  1.006 0.995  1.014  1.009 0.998  1.039  1.037  1.004 1.055 1.059 
Austria  0.997 1.013 1.010  0.997 1.011 1.008 0.995 1.019 1.014 0.997 1.039 1.036 1.002 1.055 1.058
Belgium  0.995  1.011  1.007 0.996  1.008  1.003 0.991  1.014  1.005 0.990  1.032  1.022  0.994 1.053 1.047 
Canada  1.001  1.013  1.014 0.999  1.011  1.010 0.997  1.019  1.016 1.001  1.039  1.041  1.009 1.055 1.065 
Czech  Republic  0.991 0.994 0.985  0.993 0.997 0.990 0.989 0.995 0.985 0.971 0.978 0.950 0.945 0.962 0.908
Denmark  0.998  1.013  1.010 0.996  1.008  1.004 0.992  1.014  1.005 0.992  1.034  1.026  1.000 1.055 1.055 
Finland  0.995  0.998  0.993 0.995  1.000  0.995 0.994  1.000  0.993 0.981  0.995  0.977  0.970 0.995 0.964 
France  0.995  1.013  1.008 0.995  1.009  1.004 0.991  1.016  1.006 0.986  1.039  1.024  0.985 1.055 1.039 
Germany  1.002  1.013  1.015 1.002  1.011  1.013 1.002  1.019  1.021 1.015  1.039  1.055  1.031 1.055 1.088 
Greece  1.002  1.003  1.005 1.001  1.004  1.005 1.001  1.008  1.009 1.012  1.014  1.026  1.026 1.018 1.045 
Hungary  0.994 0.994 0.988  0.998 0.997 0.996 0.998 0.996 0.994 1.016 0.977 0.993 1.077 0.961 1.035
Iceland  1.000  1.013  1.013 0.997  1.011  1.008 0.994  1.019  1.012 0.995  1.039  1.034  1.000 1.055 1.055 
Ireland  0.999  1.002  1.001 0.990  1.004  0.994 0.983  1.007  0.990 0.988  1.008  0.996  1.039 1.006 1.046 
Italy  1.008 1.005 1.013  1.006 1.005 1.011 1.009 1.010 1.019 1.026 1.015 1.042 1.044 1.018 1.063
Japan  1.000  1.002  1.002 1.000  1.003  1.003 1.000  1.006  1.006 1.000  1.008  1.008  1.000 1.006 1.006 
Korea  1.011  0.994  1.005 1.000  0.998  0.998 1.000  0.996  0.996 1.000  0.977  0.977  1.000 0.961 0.961 
Luxembourg  0.992  1.013  1.004 0.993  1.011  1.004 0.987  1.019  1.006 0.977  1.039  1.015  0.971 1.055 1.025 
Mexico  1.000  0.904  0.904 1.000  0.864  0.864 1.000  0.864  0.864 1.000  0.858  0.858  1.000 0.849 0.849 
Netherlands  1.002  1.010  1.012 0.999  1.006  1.005 0.997  1.011  1.008 1.004  1.029  1.033  1.016 1.055 1.071 
New  Zealand  0.995 0.997 0.993  0.993 0.996 0.989 0.989 0.994 0.984 0.968 0.990 0.958 0.943 1.001 0.944
Norway  1.000  1.013  1.013 0.999  1.011  1.010 0.997  1.019  1.016 1.003  1.039  1.042  1.013 1.055 1.068 
Poland  1.007  0.974  0.980 1.002  0.998  1.000 1.004  0.997  1.000 1.016  0.977  0.992  1.000 0.920 0.920 
Portugal  1.004 0.992 0.996  1.003 0.996 0.999 1.004 0.994 0.998 1.017 0.978 0.994 1.032 0.961 0.991
Slovak  Republic  0.989  0.977  0.967 0.991  0.998  0.989 0.987  0.996  0.983 0.950  0.979  0.931  0.881 0.929 0.819 
Spain  0.986  0.999  0.985 0.991  1.000  0.991 0.986  1.002  0.987 0.956  0.998  0.954  0.918 0.997 0.915 
Sweden  0.998  1.010  1.008 0.997  1.008  1.005 0.995  1.014  1.009 0.993  1.030  1.023  0.994 1.047 1.041 
Switzerland  1.000  1.013  1.013 0.999  1.011  1.010 0.997  1.019  1.016 1.000  1.039  1.040  1.006 1.055 1.061 
Turkey  1.000  0.885  0.885 1.034  0.861  0.891 1.043  0.860  0.897 1.145  0.845  0.968  1.512 0.831 1.256 
United  Kingdom 1.001 1.002 1.003  0.996 1.004 1.000 0.995 1.007 1.002 1.001 1.008 1.009 1.026 1.007 1.032
United  States  0.998  1.013  1.011 0.996  1.011  1.007 0.992  1.019  1.011 0.993  1.039  1.032  1.003 1.055 1.058 35 
 
Figure 1 Relative incremental life years (RILY) of four baseline populations 


















































Figure 2 Technical efficiency score of model based on ILYs against that based on 


























































Figure 3 Technical efficiency change of model based on ILYs against that based 

































































Figure 4 Total factor productivity change of model based on ILYs against that 

































































Figure 5 DEA frontier for the years 2000 and 2004 assuming CRS using Low 




















































Appendix B. List of lower-middle income countries used to construct the “low-
middle income” baseline population
a 
 
Albania El  Salvador  Nicaragua 
Algeria Fiji Paraguay 
Armenia Georgia  Peru 
Azerbaijan Guatemala  Philippines 
Belarus Indonesia  Samoa 
Bhutan  Iran, Islamic Rep.  Sri Lanka 
Bolivia  Iraq  Syrian Arab Republic 
Bosnia and Herzegovina  Jordan  Thailand 
Cape Verde  Kiribati  Tonga 
China Macedonia,  FYR  Tunisia 
Colombia Maldives  Turkmenistan
Cuba Marshall  Islands  Ukraine 
Dominican Republic  Micronesia Fed. Sts.  Vanuatu 
Ecuador Moldova   
Egypt, Arab Rep.  Morocco   
 
(a) The list of countries plus those in Appendix A are used jointly to construct the “low-middle 
income” baseline population. 
 
 